Tweets
The axSpA classification has been revised with the 2025 ASAS SPARTAN criteria. 5 abstracts at #EULAR2026 Abstr OP0236, OP0100, OP0239, POS0190 and POS1341.
The single most important change in the 2025 criteria: MRI is now the highest-weighted variable and what counts as a https://t.co/xg4R4xRH2D
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
2 months 3 weeks ago
AI use in rheumatology is probably going to be used the first in musculoskeletal imaging. Since patients journey is digitalised.
#EULAR2026 @RheumNow
We are drowning in healthcare data. https://t.co/61HqtSCQxC
Links:
Bella Mehta @bella_mehta ( View Tweet )
2 months 3 weeks ago
+#RCT in #dermatomyositis with #brepocitinib
Oral #TYK2/JAK1i
241 pts
+outcomes
#TIS total improvement score
>40%TIS 68% v 44%
#steroid tapering
#skin improved rapidly #CLASI
#OP0166
#POS0264 @RheumNow #EULAR2026 https://t.co/9WZl9RsXXe
Links:
Janet Pope @Janetbirdope ( View Tweet )
2 months 3 weeks ago
#EULAR2026 POS0306 Can we predict #lupus nephritis pts who would achieve CR at 12 mths? Monocentric study used M.Learning: developed & internally validated 5 Clinical Score (LUPRED) with AUC 0.75 training set, 0.78 validation. Simple to use but needs external validation @RheumNow https://t.co/1VRE1yBCac
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 months 3 weeks ago
Digitalization in rheumatology.
How can it help?
Potential opportunities
@RheumNow #EULAR2026 https://t.co/KKImSNLgbq
Links:
Bella Mehta @bella_mehta ( View Tweet )
2 months 3 weeks ago
Can we finally personalize MTX dosing in #RA? liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay (n=59): MTX-PG3 levels ↑ with dose and age, ↓ with higher disease activity and concomitant biologics. Route (oral vs SC) didn't matter. @RheumNow #EULAR2026 POS0251
Jiha Lee @JihaRheum ( View Tweet )
2 months 3 weeks ago
SPARTAN-SSR: New quantitative criteria: BME in ≥3 consecutive slices OR any two of (BME, Erosion, Fat lesion each in ≥3 SIJ quadrants) or ankylosis in ≥3 halves achieves 88-96% sensitivity and 90-98% specificity across 3 cohorts. Precision #axSpA imaging. Abstr OP0100
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
2 months 3 weeks ago
#EULAR2026 POS0713 Is there a hope for BTK-inhibition in #SLE despite several previous failures? A Phase IIb RCT in China: primary endpoint (SRI-4) was met in Orelabrutinib vs PBO in dose-dependent manner. No new safety signal. Phase 3 RCT is underway @RheumNow https://t.co/4cJ8ezppTS
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 months 3 weeks ago
Gecacitinib (pan-JAK inhibitor) vs placebo in radiographic #axSpA ASAS40 51.9% vs 12.9% (p<0.0001) at 16 weeks. ASAS20 69.2% vs 21.2% (p<0.0001). Pan-JAK inhibition showed efficacy in TNFi-experienced patients. Abstr OP0240 @RheumNow #EULAR2026
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
2 months 3 weeks ago
#proof of #concept in #Sjogren’s #dis
#lanalumab Treatment reduced in #SjD
✅reduced B cells in #salivary #glands
—nearly complete depletion in serum
✅reduced B cell activation
✅improved #inflammation of
#parotid & #submandibular glands
@RheumNow #EULAR2026
#OP0163
#POS0284
Janet Pope @Janetbirdope ( View Tweet )
2 months 3 weeks ago
Interim results from ASTER, a study on real world effectiveness of ANI in SLE: Pts receiving ANI had improvements in total SLEDAI-2K scores after 1 yr ffup period
MCT, MSK & hema had the highest decrease in SLEDAI-2K scores from pre-tx to 1yr ffup
OP342 @RheumNow #EULAR2026 https://t.co/DArOwQtxM6
Links:
sheila @RHEUMarampa ( View Tweet )
2 months 3 weeks ago
ETA+MTX vs triple therapy after MTX failure in #RA: machine learning-emulated RACAT trial (n=3,472 VA pts) confirms ETA+MTX modestly better overall. But smoking matters: benefit disappears in current smokers. Precision medicine from RWD. @RheumNow #EULAR2026 POS0255
Jiha Lee @JihaRheum ( View Tweet )
2 months 3 weeks ago
Baricitinib inhibits substance P and IL6 - by interfering with the pathway NGF-IL6-SP axis. This is a novel pathway to pain suppression in RA
#EULAR2026 #pos0217 @rheumnow https://t.co/6MsrFH3Mm0
Bella Mehta @bella_mehta ( View Tweet )
2 months 3 weeks ago
#EULAR2026 POS0156 “TWO’S company, THREE’S a crowd” Tri-specific CD19/CD3/CD28 (i.e. CD28 co-stimulates Tcell activation) TriTE via IV showed early efficacy & safety in 11 #SLE patients up to 48WKS. Longer FU needed to see if repeat dosing needed @RheumNow https://t.co/FpXzJIYwZF
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 months 3 weeks ago
Rapcabtagene Autoleucel -YTB323 rapidly manufactured CD19 CAR T
#POS0303 #EULAR2026 @RheumNow
24 months follow up data for 21 pts.
Durable b cell reduction and decrease in disease activity. https://t.co/m3lYjZJJIy
Links:
Bella Mehta @bella_mehta ( View Tweet )
2 months 3 weeks ago
